A股異動丨蘇州高新四連板 正籌劃對醫療器械產業公司增資 以實現控股且並表
格隆匯3月21日丨蘇州高新(600736.SH)連續第四個交易日漲停,報7.22元創近兩年半新高,總市值83億元。蘇州高新上週五晚間公吿,公司正在籌劃對醫療器械產業公司實施現金增資,並對交易標的實現控股且並表。本次增資正在進行審計評估,增資價格、增資金額以及增資後公司的持股比例尚未確定;公司未與醫療器械產業公司或其現股東簽訂與本次增資相關的意向性協議。醫療器械產業公司為公司控股股東蘇高新集團的控股子公司,根據相關規定,本次增資構成關聯交易。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.